Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting
Ozanimod demonstrated superiority versus interferon beta-1a (Avonex®) in reducing annualized relapse rates and MRI brain lesions at two years Incidence of adverse events and serious adverse ev......
